Current Concepts: Osteo-Core-Plasty
Szwedowski D, Herman K, Bizzoco L, Montagna A.
ISAKOS Newsletter 2023, Vol. 1
Indications: Subchondral bone marrow edema (BME) and cysts
Procedure: Osteo-Core-Plasty (OCP) to treat subchondral pathologies in knee osteoarthritis
Technique: Use of Marrow Cellution™ System to harvest specialized bone marrow and vascularized bone cores, implantation to promote bone remodeling
Postoperative Care: Pain management, maintaining range of motion, preventing muscle atrophy
Rehabilitation: Continuous passive motion and cryo-cuff immediately post-op / isometric and isotonic exercises from day 2 / touch-down weight-bearing at 3-4 weeks / full weight-bearing at ~6 weeks / pool exercises after wound healing
Outcomes: Promising clinical results
Introduction
Subchondral bone is responsible for cartilage nutrition and plays an important role in the healing of chondral lesions. There are two major parts of subchondral bone: the bone plate and the spongiosa. Subchondral bone remains an underappreciated element of joint health and should be viewed as a critical part of the osteochondral unit. In patients with knee osteoarthritis, subchondral bone marrow edema (BME) correlates with faster joint degeneration and more pain. Although there are limited treatment options involving the subchondral bone, a great deal of research is being conducted on the use of biologics to maintain and improve cartilage health.
A relatively new, minimally invasive procedure for treating subchondral pathologies in order to prevent the development of osteoarthritis is Osteo-Core-Plasty (OCP). Typically, osteoarthritis-related subchondral cysts and painful BME are the indications.
The OCP procedure involves the utilization and implementation of the Marrow Cellution Bone Marrow Collection and Autologous Bone Core Harvesting System to collect and percutaneously inject highly specialized bone marrow and intact vascularized bone core cylinders into the region of BME to repopulate the intertrabecular space, thereby improving bone remodeling.
______________________________________________________
The Marrow Cellution™ System is designed to minimize and eliminate the restrictive limitations associated with “point of care” processing systems which employ inefficient traditional aspiration trocar technology and are regulated as drugs “Advanced Therapies Medicinal Products (ATMP)”. Marrow Cellution™ is a minimally invasive bone/cell enriched autograft access and retrieval system, which does not require additional manipulation or processing, it never leaves the sterile field and provides rich autograft without associated morbidity.
Visit our Marrow Cellution product page
